| Item Type | Name |
|
Concept
|
Antibodies, Neoplasm
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Antibodies, Bispecific
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Antibodies, Monoclonal, Murine-Derived
|
|
Academic Article
|
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
|
|
Academic Article
|
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
|
Academic Article
|
Burkitt lymphoma/leukemia: improving prognosis.
|
|
Academic Article
|
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
|
|
Academic Article
|
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
|
|
Academic Article
|
Chimerism does not predict for outcome after alemtuzumab based conditioning.
|
|
Academic Article
|
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
|
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
|
|
Academic Article
|
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
|
|
Academic Article
|
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
|
|
Academic Article
|
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
|
|
Academic Article
|
Novel drug targets in acute leukemia.
|
|
Academic Article
|
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
|
|
Academic Article
|
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.
|
|
Academic Article
|
Should immunologic strategies be incorporated into frontline ALL therapy?
|
|
Academic Article
|
"Dar"-ing to target CD38 in T-ALL.
|
|
Academic Article
|
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.
|
|
Academic Article
|
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
|
|
Academic Article
|
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
|
|
Academic Article
|
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
|
|
Academic Article
|
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents.
|
|
Academic Article
|
Biotinylated steroid derivatives as ligands for biospecific interaction analysis with monoclonal antibodies using immunosensor devices.
|
|
Academic Article
|
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
|